Targeting acetyl-CoA carboxylases for the treatment of MASLD
Journal of Lipid Research · 2024-12 · 65 (12) · 100676
DOI: 10.1016/j.jlr.2024.100676 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Lipid Research, 2024-12. Verfasst von María Antonia Mateo-Marín und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Biotechnology and Public Health, Biomedical Research and Innovation Institute of Cadiz (INiBICA), Faculty of Medicine, Uni…. Hauptthemen laut MEDLINE: Acetyl-CoA Carboxylase, Fatty Liver. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigación, Universidad de Cádiz, Junta de Andalucía.
Abstract (Originalsprache)
Hepatic accumulation of triglycerides is a hallmark feature of metabolic dysfunction-associated steatotic liver disease (MASLD). Growing evidence indicates that increased rates of de novo lipogenesis (DNL) are one of the earliest metabolic changes promoting hepatic steatosis in the onset of MASLD. The first step in DNL is catalyzed by acetyl-CoA carboxylases (ACC), which mediate the conversion of acetyl-CoA into malonyl-CoA. Given the critical role of ACC enzymes on DNL, ACC-based therapies have emerged as an attractive approach to address MASLD, leading to the development of pharmacologic inhibitors of ACC. In clinical trials, several of those compounds led to decreased DNL rates and improved hepatic steatosis in patients with MASLD. In this review, we describe the development of ACC dual inhibitors and isoform-specific inhibitors along with their clinical testing using monotherapy and combination therapy approaches. We also discuss their efficacy and safety profiles, identifying potential directions for future research. It is anticipated that advances in ACC-based therapies will be critical to the management of MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, Biotechnology and Public Health, Biomedical Research and Innovation Institute of Cadiz (INiBICA), Faculty of Medicine, University of Cadiz, Cadiz, Spain.
- Department of Biomedicine, Biotechnology and Public Health, Biomedical Research and Innovation Institute of Cadiz (INiBICA), Faculty of Medicine, University of Cadiz, Cadiz, Spain. Electronic address: michele.alves@uca.…
Förderung
- Agencia Estatal de Investigación
- Universidad de Cádiz
- Junta de Andalucía
Zitieren
APA
Mateo-Marín, M. A., & Alves-Bezerra, M. (2024). Targeting acetyl-CoA carboxylases for the treatment of MASLD. Journal of Lipid Research, 65(12), 100676. https://doi.org/10.1016/j.jlr.2024.100676
Vancouver
Mateo-Marín MA, Alves-Bezerra M. Targeting acetyl-CoA carboxylases for the treatment of MASLD. Journal of Lipid Research. 2024;65(12):100676. doi:10.1016/j.jlr.2024.100676
BibTeX
@article{MateoMarn2024,
author = {Mateo-Marín, María Antonia and Alves-Bezerra, Michele},
title = {Targeting acetyl-CoA carboxylases for the treatment of MASLD},
journal = {Journal of Lipid Research},
year = {2024},
volume = {65},
number = {12},
pages = {100676},
doi = {10.1016/j.jlr.2024.100676}
}
EUVIMED